Which has preferable earnings and valuation, ELAN or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Elanco Animal Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elanco Animal Health $4.72B 2.38 -$232M -$0.41 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media prefer ELAN or RGC?

In the previous week, Elanco Animal Health had 6 more articles in the media than Regencell Bioscience. MarketBeat recorded 8 mentions for Elanco Animal Health and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.69 beat Elanco Animal Health's score of 0.17 indicating that Regencell Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RGC or RDY?

Dr. Reddy's Laboratories has a consensus target price of $1,450.00, suggesting a potential upside of 11,770.65%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, RGC or RDY?

Dr. Reddy's Laboratories has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Dr. Reddy's Laboratories $3.58B 2.85 $456M $0.44 27.76

Does the media favor RGC or RDY?

In the previous week, Regencell Bioscience and Regencell Bioscience both had 2 articles in the media. Regencell Bioscience's average media sentiment score of 0.69 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Regencell Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AXSM or RGC?

Axsome Therapeutics currently has a consensus price target of $275.74, indicating a potential upside of 62.12%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 1 Sell rating(s) 2 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.86 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, AXSM or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Axsome Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Axsome Therapeutics $776.57M 11.47 -$183.17M -$3.75 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media favor AXSM or RGC?

In the previous week, Axsome Therapeutics had 9 more articles in the media than Regencell Bioscience. MarketBeat recorded 11 mentions for Axsome Therapeutics and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.69 beat Axsome Therapeutics' score of 0.15 indicating that Regencell Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RGC or CRNX?

Crinetics Pharmaceuticals has a consensus target price of $83.44, suggesting a potential downside of 1.77%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Crinetics Pharmaceuticals 1 Sell rating(s) 11 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13

Which has preferable valuation and earnings, RGC or CRNX?

Regencell Bioscience has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Crinetics Pharmaceuticals $7.70M 1,170.54 -$465.32M -$5.04 N/A

Do analysts recommend RGC or BLTE?

Belite Bio has a consensus price target of $218.73, indicating a potential upside of 43.41%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Belite Bio 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Which has preferable valuation & earnings, RGC or BLTE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is RGC or BLTE more profitable?

Regencell Bioscience's return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Belite Bio N/A -11.84% -11.62%

Does the media favor RGC or BLTE?

In the previous week, Belite Bio had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Belite Bio and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.69 beat Belite Bio's score of 0.31 indicating that Regencell Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Regencell Bioscience (RGC) Competitors

$7.63 +0.52 (+7.31%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$7.72 +0.09 (+1.18%)

As of 08:47 AM Eastern

Compare

RGC vs. ELAN, RDY, AXSM, CRNX, and BLTE

Should you buy Regencell Bioscience stock or one of its competitors? Regencell Bioscience's main competitors and comparable companies include Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Axsome Therapeutics (AXSM), Crinetics Pharmaceuticals (CRNX), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Regencell Bioscience compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Regencell Bioscience has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Regencell Bioscience	N/A	N/A	N/A

In the previous week, Elanco Animal Health had 6 more articles in the media than Regencell Bioscience. MarketBeat recorded 8 mentions for Elanco Animal Health and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.69 beat Elanco Animal Health's score of 0.17 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has lower revenue, but higher earnings than Elanco Animal Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.38	-$232M	-$0.41	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Elanco Animal Health presently has a consensus target price of $29.70, indicating a potential upside of 32.03%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe Elanco Animal Health is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Elanco Animal Health has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Summary

Elanco Animal Health beats Regencell Bioscience on 10 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Regencell Bioscience (NASDAQ:RGC) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Regencell Bioscience and Regencell Bioscience both had 2 articles in the media. Regencell Bioscience's average media sentiment score of 0.69 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Regencell Bioscience's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Dr. Reddy's Laboratories has a consensus target price of $1,450.00, suggesting a potential upside of 11,770.65%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Regencell Bioscience has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Dr. Reddy's Laboratories	$3.58B	2.85	$456M	$0.44	27.76

Summary

Dr. Reddy's Laboratories beats Regencell Bioscience on 9 of the 11 factors compared between the two stocks.

How does Regencell Bioscience compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Regencell Bioscience (NASDAQ:RGC) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Axsome Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 9 more articles in the media than Regencell Bioscience. MarketBeat recorded 11 mentions for Axsome Therapeutics and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.69 beat Axsome Therapeutics' score of 0.15 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics currently has a consensus price target of $275.74, indicating a potential upside of 62.12%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Regencell Bioscience has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. Regencell Bioscience's return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Regencell Bioscience	N/A	N/A	N/A

Regencell Bioscience has lower revenue, but higher earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	11.47	-$183.17M	-$3.75	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Summary

Axsome Therapeutics beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Crinetics Pharmaceuticals?

Regencell Bioscience (NASDAQ:RGC) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Regencell Bioscience had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 2 mentions for Regencell Bioscience and 0 mentions for Crinetics Pharmaceuticals. Regencell Bioscience's average media sentiment score of 0.69 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Positive
Crinetics Pharmaceuticals	Neutral

Regencell Bioscience has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Regencell Bioscience's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Crinetics Pharmaceuticals has a consensus target price of $83.44, suggesting a potential downside of 1.77%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Regencell Bioscience has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Regencell Bioscience has higher earnings, but lower revenue than Crinetics Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Summary

Regencell Bioscience beats Crinetics Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to Belite Bio?

Regencell Bioscience (NASDAQ:RGC) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Regencell Bioscience has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

In the previous week, Belite Bio had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Belite Bio and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.69 beat Belite Bio's score of 0.31 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio has a consensus price target of $218.73, indicating a potential upside of 43.41%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Regencell Bioscience's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Belite Bio	N/A	-11.84%	-11.62%

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Belite Bio beats Regencell Bioscience on 6 of the 11 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGC vs. The Competition

Export

Metric	Regencell Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.52B	$12.35B	$7.19B	$13.37B
Dividend Yield	N/A	2.64%	2.53%	16.36%
P/E Ratio	N/A	800.12	274.66	26.04
Price / Sales	N/A	787.34	568.58	76.65
Price / Cash	N/A	86.17	76.82	53.72
Price / Book	763.00	10.74	10.88	6.27
Net Income	-$3.58M	$2.83B	$3.50B	$382.01M
7 Day Performance	11.88%	-1.35%	-1.84%	-1.60%
1 Month Performance	30.43%	-6.14%	-6.36%	-4.63%
1 Year Performance	-58.62%	-6.03%	3.07%	-0.95%

Regencell Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGC Regencell Bioscience	0.7009 of 5 stars	$7.63 +7.3%	N/A	-60.7%	$3.52B	N/A	N/A	10	News Coverage Earnings Report
ELAN Elanco Animal Health	3.8347 of 5 stars	$22.45 -0.7%	$29.70 +32.3%	+10.6%	$11.30B	$4.72B	N/A	9,400	News Coverage
RDY Dr. Reddy's Laboratories	3.9965 of 5 stars	$12.63 -1.8%	$1,450.00 +11,385.1%	-12.8%	$10.73B	$3.58B	28.69	27,527
AXSM Axsome Therapeutics	3.4367 of 5 stars	$184.39 -0.9%	$271.00 +47.0%	+43.3%	$9.75B	$638.50M	N/A	925	Analyst Forecast
CRNX Crinetics Pharmaceuticals	0.8191 of 5 stars	$84.95 flat	$83.44 -1.8%	N/A	$9.01B	$7.70M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGC) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regencell Bioscience (RGC) Competitors

RGC vs. ELAN, RDY, AXSM, CRNX, and BLTE

How does Regencell Bioscience compare to Elanco Animal Health?

Summary

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Summary

How does Regencell Bioscience compare to Axsome Therapeutics?

Summary

How does Regencell Bioscience compare to Crinetics Pharmaceuticals?

Summary

How does Regencell Bioscience compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regencell Bioscience (RGC) Competitors

RGC vs. ELAN, RDY, AXSM, CRNX, and BLTE

How does Regencell Bioscience compare to Elanco Animal Health?

Is ELAN or RGC more profitable?

Does the media prefer ELAN or RGC?

Which has preferable earnings and valuation, ELAN or RGC?

Do institutionals & insiders believe in ELAN or RGC?

Do analysts recommend ELAN or RGC?

Which has more volatility and risk, ELAN or RGC?

Summary

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Do insiders and institutionals have more ownership in RGC or RDY?

Does the media favor RGC or RDY?

Is RGC or RDY more profitable?

Do analysts rate RGC or RDY?

Which has more risk & volatility, RGC or RDY?

Which has higher earnings and valuation, RGC or RDY?

Summary

How does Regencell Bioscience compare to Axsome Therapeutics?

Which has more risk & volatility, AXSM or RGC?

Do insiders & institutionals believe in AXSM or RGC?

Does the media favor AXSM or RGC?

Do analysts recommend AXSM or RGC?

Is AXSM or RGC more profitable?

Which has higher valuation & earnings, AXSM or RGC?

Summary

How does Regencell Bioscience compare to Crinetics Pharmaceuticals?

Does the media refer more to RGC or CRNX?

Is RGC or CRNX more profitable?

Do analysts rate RGC or CRNX?

Which has more volatility & risk, RGC or CRNX?

Do insiders & institutionals have more ownership in RGC or CRNX?

Which has preferable valuation and earnings, RGC or CRNX?

Summary

How does Regencell Bioscience compare to Belite Bio?

Which has more volatility & risk, RGC or BLTE?

Does the media favor RGC or BLTE?

Do analysts recommend RGC or BLTE?

Which has preferable valuation & earnings, RGC or BLTE?

Is RGC or BLTE more profitable?

Do insiders & institutionals believe in RGC or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools